Please assess the completion status of the following clinical trial:

Trial Title: PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a pre-menopausal woman aged between 18 and 48 years inclusive.~* Subject with a Body Mass Index ≥18 and ≤40.~* Subject with myomatous uterus size \< 16 weeks.~* Subject must have at least one uterine myoma of at least 3 cm diameter in size and no myoma larger than 10 cm diameter diagnosed by ultrasound.~* Subject complained of strong uterine bleeding.~* Subject is eligible for hysterectomy or myomectomy.~* Females of childbearing potential have to practice a non-hormonal method of contraception.~Exclusion Criteria:~* Subject has a history of or current uterus, cervix, ovarian or breast cancer.~* Subject has a history of endometrium hyperplasia or adenocarcinoma in a biopsy performed within the past 6 months or similar lesions in the screening biopsy.~* Subject has a known severe coagulation disorder.~* Subject has a history of treatment for myoma with a SPRM, including ulipristal acetate.~* Subject has abnormal hepatic function at study entry.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
- B (Type: EXPERIMENTAL): Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets).

Based on this trial design, predict the completion outcome and termination type (if applicable).